Treatment of RSV in Pediatric Patients

Core Treatment Principles

The American Academy of Pediatrics recommends that RSV treatment in children is purely supportive care, with no effective antiviral therapy for routine use, and palivizumab is only for prevention in high-risk infants, never for treatment of active infection 1, 2, 3
Oxygen supplementation is recommended when saturation falls persistently below 90% in previously healthy infants 2, 3
Hydration support through oral fluids or nasogastric/intravenous routes is recommended if the infant cannot maintain adequate oral intake 2, 4
Fever and pain management with acetaminophen or ibuprofen is recommended as needed 2
Nasal saline irrigation is recommended for symptomatic relief of upper respiratory symptoms 2

The American Academy of Pediatrics recommends hospitalization for infants with hypoxemia, severe respiratory distress, inability to maintain adequate oral intake, or underlying high-risk conditions 2, 3, 4
Infants under 3 months are at the highest risk for severe disease and may require hospitalization 1

The Centers for Disease Control and Prevention recommends considering antiviral therapy for high-risk immunocompromised groups, including hematopoietic stem cell transplant recipients, solid organ transplant recipients, and patients with profound lymphopenia 2, 3
Aerosolized ribavirin is the primary option for HSCT patients with RSV lower respiratory tract infection, though evidence is based mainly on observational data 2, 3
Systemic ribavirin dosing schedule is recommended as follows: 600 mg loading dose, then 200 mg every 8 hours on day 1, 400 mg every 8 hours on day 2, and increase to maximum of 10 mg/kg every 8 hours on day 3 onward 2

The Centers for Disease Control and Prevention recommends hand hygiene as the single most important measure to prevent RSV transmission and nosocomial spread 2, 3
Key infection control measures include hand decontamination, use of gowns and gloves, and droplet precautions for all children under 2 years with respiratory symptoms during RSV season 2

The American Academy of Pediatrics recommends discharge when patients meet certain criteria, including oxygen saturation consistently above 90% in room air, clinical improvement, and absence of substantially increased work of breathing 2

The American Academy of Pediatrics recommends palivizumab prophylaxis for high-risk populations, including infants born at or below 28 weeks gestation, infants with bronchopulmonary dysplasia, and children with hemodynamically significant congenital heart disease 1, 5, 6
Nirsevimab, a long-acting monoclonal antibody, is now recommended by the CDC for all infants under 8 months entering their first RSV season as a single dose 2, 4